002437: HARBIN GLORIA PHARMACEUTICALS Co., LTD - Summary | Jitta

HARBIN GLORIA PHARMACEUTICALS Co., LTD

CHN:002437

Price
CN¥4.53
Loss Chance
47.5%
5.50JITTA SCORE
99.08%Over Jitta Line
Jitta Ranking
74 / 486
875 / 5,270
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (45)
Recent Business Performance (67)
Financial Strength (88)
Return to Shareholders (25)
Competitive Advantage (44)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing Every Year
Revenue and EarningRevenue decline from 2022-2025
Key Stats
Jitta Score
Jitta Line
5.50
99.08%
4.40
> 1,000%
4.23
> 1,000%
Pharmaceuticals
7.55
2.58%
5.63
16.32%
7.34
27.35%
COMPANY DESCRIPTION
HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride sustained-release tablets, sodium creatine phosphate for injection, ginkgo biloba extract injections, vitamins (B12), fluorouracil for injection, bleomycin hydrochloride for injection, and other injectable products, as well as pravastatin sodium tablets, olmesartan medoxomil amlodipine tablets, and edoxaban tosylate tablets. In addition, the company engages in pharmaceutical promotion; project investment; investment services; trade import and export; wholesale and retail; and technology promotion and application services. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is headquartered in Harbin, the People’s Republic of China.